Plakous Therapeutics develops human placental extract (HPE) biotherapeutics that possess anti-inflammatory and immunomodulatory properties to treat inflammation-driven diseases such as necrotizing enterocolitis and osteoarthritis. Their technology aims to restore and repair damaged organs by orchestrating a complex cellular response, significantly reducing disease severity and protecting joint cartilage in preclinical models.
Funding
$17.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inflammation-driven diseases, ranging from necrotizing enterocolitis in infants to osteoarthritis in older adults, pose significant challenges due to the body's inability to effectively repair damaged organs. Current treatments often fail to fully address the underlying inflammatory processes and restore tissue function.
Solution
Plakous Therapeutics develops regenerative biotherapeutics derived from human placental extract (HPE) to treat inflammation-driven diseases. Their HPE-based biologics possess anti-inflammatory and immunomodulatory properties that orchestrate a complex cellular response to restore and repair organs damaged by inflammation. Preclinical studies have demonstrated that HPE significantly reduces disease severity in necrotizing enterocolitis and protects joint cartilage in osteoarthritis models. The company's lead candidate has received rare pediatric and orphan drug designations for its potential in preventing necrotizing enterocolitis.
Target Audience
The primary target audience includes patients suffering from inflammation-driven diseases such as necrotizing enterocolitis and osteoarthritis, as well as healthcare providers seeking innovative regenerative therapies.
Features
- Human placental extract (HPE) with anti-inflammatory and immunomodulatory properties
- Orchestrates a complex cellular response to restore and repair damaged organs
- Demonstrated significant reduction in disease severity in preclinical models of necrotizing enterocolitis
- Showed significant protection of joint cartilage in preclinical models of osteoarthritis
- Received rare pediatric and orphan drug designations for potential in preventing necrotizing enterocolitis